Open AccessThe experience of a comprehensive assessment of the effectiveness of antihypertensive therapy in clinical practice
Author(s) -
Svetlana A. Solgalova,
Tatyana V. Glukhova,
И. А. Знаменская,
И. Б. Романова
Publication year - 2019
Publication title -
medicinskij vestnik ûga rossii
Language(s) - English
Resource type - Journals
eISSN - 2618-7876
pISSN - 2219-8075
DOI - 10.21886/2219-8075-2019-10-3-62-71
Subject(s) - perindopril , indapamide , medicine , blood pressure , essential hypertension , combination therapy , pharmacology , oral administration , urology
Objective: to study the antihypertensive efficacy of a new dosage form of perindopril A — tablets dispersed in the oral cavity — in the group of patients with arterial hypertension (AH) on an outpatient basis. Material and methods: the study included 30 patients (mean age 53.8 ± 0.9 years) with the presence of arterial hypertension, diagnosed initially, or with no control of blood pressure at the background of previous antihypertensive therapy. All investigators were administered perindopril A in the form of a dispersible form in a dose of 10 mg in monotherapy or in combination with indapamide – in case of failure to achieve target blood pressure after 2 weeks of observation. The total duration of the study is 3 months. Results: by the end of the observation, the SBP / DBP decreased by 35.6 ± 2.3 / 16.5 ± 1.0 mm Hg. Correction of therapy with the addition of indapamide-retard was required in 6 (20%) patients. Effective antihypertensive therapy was accompanied by a significant decrease in daily (according to ICBP data), intravisit, and visit-to-visit variability of the SBP, which was 4.4 mm Hg in terms of standard deviation by the end of the observation. The use of a new dosage form of perindopril A was accompanied by a significant increase in adherence to therapy. Conclusion: the use of a new dosage form of perindopril A — tablets dispersed in the oral cavity — in monotherapy or in combination with indapamide-retard can improve the treatment of patients with hypertension who do not have target BP values.